Introduction In August 2019, the First Hospital of Jilin University initiated the establishment of Jilin Jianglin Biotechnology Co., Ltd. Building on the preliminary research into the mechanisms of human diseases and the early stages of drug development by the Epigenetic Medicine Institute of Jilin University’s First Hospital, and in collaboration with the American company Parkside, Jianglin Biotechnology was founded, specializing in the development of pioneering small molecule targeted therapies. Leaning on groundbreaking scientific discoveries in the field of epigenetics and focusing on genes associated with disease onset and progression and their transcriptional expression, Jianglin Biotechnology is dedicated to providing innovative therapeutic drugs and treatment approaches for patients with malignant tumors and immune-inflammatory diseases. |